Results 211 to 220 of about 5,904 (237)
Some of the next articles are maybe not open access.
American Journal of Therapeutics, 1997
Capitolo di libro didattico per studenti di ...
Debora Karetová +3 more
openaire +5 more sources
Capitolo di libro didattico per studenti di ...
Debora Karetová +3 more
openaire +5 more sources
Alprostadil for the treatment of erectile dysfunction
Expert Opinion on Investigational Drugs, 1999Erectile dysfunction (ED) is a common medical condition affecting over 20 m men in the United States. Efficacious medical therapy for the treatment of erectile dysfunction has been available since the early 1980s and can be divided into local pharmacotherapy and systemic therapy.
openaire +3 more sources
Intraurethral Alprostadil Training
2016Intraurethral alprostadil suppository is available on the market under the trade name MUSE® (Medicated Urethral System for Erection, Meda Pharmaceuticals Inc. Somerset, NJ). The medication is placed within the urethra and is absorbed via retrograde venous channels between the corpus spongiosum and corpora cavernosa.
Lawrence C. Jenkins, John P. Mulhall
openaire +2 more sources
Efficacy and Safety of Intracavernosal Alprostadil in Men With Erectile Dysfunction
Obstetrical & Gynecological Survey, 1996Background Erectile dysfunction is a common medical problem affecting many men. Although several intracavernosal therapies are available, their efficacy and safety have not been studied systematically. Methods We investigated the efficacy and safety of alprostadil formulated for intracavernosal treatment in three separate multi-institutional ...
Francis G. Ogrinc, Otto I. Linet
openaire +3 more sources
Intraurethral Alprostadil for Erectile Dysfunction
Drugs, 2012The global burden of erectile dysfunction (ED) is increasing. It is estimated that 8-19% of men in Europe have ED and that by 2025 the prevalence of ED worldwide will reach 322 million. The gold standard therapy for ED is an oral phosphodiesterase type 5 (PDE5) inhibitor, but they are not suitable for everyone; approximately 25% of patients do not ...
Axel-Juerg Potempa, Pierre Costa
openaire +3 more sources
Does alprostadil cream hit the spot?
Drug and Therapeutics Bulletin, 2015Alprostadil, a prostaglandin, has been marketed for many years as a urethral stick and an intracavernous injection for the treatment of erectile dysfunction.1It is now available in the form of a cream (Vitaros—Takeda). Adverts for the product declare: “Sex with no pills, pellets or needles.
openaire +2 more sources
Topical alprostadil cream for the treatment of erectile dysfunction
Expert Opinion on Pharmacotherapy, 2004Erectile dysfunction (ED) has serious negative consequences on both sexual experience and emotional well being and affects a broad range of age groups. The prevalence of ED is associated with increasing age and has been reported to be as high as 70%. Although the disorder is common and underdiagnosed, its treatment can significantly improve patients ...
openaire +2 more sources
Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon
Scandinavian Journal of Rheumatology, 2004The prostanoids iloprost and alprostadil are widely used to treat ischaemic changes in patients with Raynaud's phenomenon (RP), but the optimal regimen is poorly defined. We evaluated whether there are differences between iloprost and alprostadil, in terms of either clinical efficacy or of laboratory data, with the aim of assisting in the treatment of ...
B. Marasini +7 more
openaire +4 more sources
Clitoral Hemodynamic Changes after a Topical Application of Alprostadil
Journal of Sex & Marital Therapy, 2001We performed duplex ultrasonography of the clitoris to assess the local hemodynamic changes after a topical application of alprostadil. Color duplex ultrasonography was used to evaluate 18 women before and after the application of 1 g of 0.2% alprostadil gel.
Edgardo Becher +2 more
openaire +3 more sources
Influence of alprostadil on pulmonary dysfunction after a cardiac operation
The Annals of Thoracic Surgery, 1992To test the effects of alprostadil on pulmonary dysfunction after cardiac operations, we studied 24 male patients undergoing aortocoronary bypass. Twelve were given an intravenous infusion of alprostadil (synthetic prostaglandin E1), 20 ng.kg-1.min-1, in a double-blind manner during operation; the other 12 were controls.
Abdusalam El-Gatit +4 more
openaire +3 more sources